Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells

被引:20
|
作者
Lin, Yi-Te [1 ]
Chao, Chuck C. -K. [1 ,2 ]
机构
[1] Chang Gung Univ, Grad Inst Biomed Sci, Coll Med, Taoyuan 33302, Taiwan
[2] Chang Gung Univ, Dept Biochem & Mol Biol, Coll Med, Taoyuan 33302, Taiwan
关键词
apoptosis; hepatocellular carcinoma; beta-catenin; prothymosin; sorafenib; PROTHYMOSIN-ALPHA; C-MYC; MESSENGER-RNA; CATENIN GENE; SOMATIC MUTATIONS; INDUCED APOPTOSIS; CROSS-RESISTANCE; CANCER-CELLS; COLON-CANCER; EXPRESSION;
D O I
10.18632/oncotarget.5738
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sorafenib is a kinase inhibitor used as anticancer drug against various human tumors, including advanced hepatocellular carcinoma (HCC). beta-Catenin and prothymosin alpha (PTMA) are overexpressed in HCC and other tumors. Previous studies have shown that PTMA expression modulates the response of HCC cells to sorafenib. However, the underlying mechanism of PTMA activity in this context remains unclear. We show here that sorafenib inhibits both beta-Catenin and PTMA in a dose-dependent manner. Silencing beta-Catenin reduces PTMA level and sensitizes HCC cells to sorafenib. In contrast, ectopic expression of beta-Catenin induces PTMA expression and cell resistance to the drug. Sorafenib inhibits PTMA expression at the transcriptional level by inhibiting the beta-Catenin pathway. Nucleotide deletion analysis of the PTMA gene promoter reveals that a DNA segment lying 1,500-1,600 bp upstream of the PTMA transcription start site represents an AP-1-binding site that is critical for beta-Catenin modulation of gene transcription in response to sorafenib. In addition, chemical inhibitors that target JNK abrogate beta-Catenin/AP-1 binding to the endogenous PTMA gene and reduces PTMA transcription and protein expression. Silencing of beta-Catenin or c-Fos induces similar effects on gene regulation and these are reversed by ectopic expression of beta-Catenin. Mutations in the PTMA promoter at the predicted beta-Catenin/AP-1 binding site partly abrogate sorafenib's effects on PTMA transcription. These results indicate that PTMA is induced by the oncoprotein beta-Catenin and protects HCC cells against sorafenib-induced cell death. The beta-Catenin/JNK/PTMA axis may thus represent a novel target for chemotherapy against HCC.
引用
收藏
页码:38999 / 39017
页数:19
相关论文
共 50 条
  • [1] Inhibition of JNK and prothymosin-alpha sensitizes hepatocellular carcinoma cells to cisplatin
    Lin, Yi-Te
    Liu, Yu-Chin
    Chao, Chuck C. -K.
    BIOCHEMICAL PHARMACOLOGY, 2016, 122 : 80 - 89
  • [2] Oncogenic c-Myc and prothymosin-alpha protect hepatocellular carcinoma cells against sorafenib-induced apoptosis
    Lin, Yi-Te
    Lu, Hsing-Pang
    Chao, Chuck C. -K.
    BIOCHEMICAL PHARMACOLOGY, 2015, 93 (01) : 110 - 124
  • [3] Overexpression of hepatic prothymosin alpha, a novel marker for human hepatocellular carcinoma
    CG Wu
    NA Habib
    RR Mitry
    PH Reitsma
    SJ van Deventer
    RA Chamuleau
    British Journal of Cancer, 1997, 76 : 1199 - 1204
  • [4] Overexpression of hepatic prothymosin alpha, a novel marker for human hepatocellular carcinoma
    Wu, CG
    Habib, NA
    Mitry, RR
    Reitsma, PH
    vanDeventer, SJH
    Chamuleau, RAFM
    BRITISH JOURNAL OF CANCER, 1997, 76 (09) : 1199 - 1204
  • [5] IDENTIFICATION OF NOVEL CHEMOTYPES TARGETING β-CATENIN IN HEPATOCELLULAR CARCINOMA
    Delgado, Evan
    Mannam, Harshitha
    Strom, Stephen
    Mustata, Gabriela
    Monga, Satdarshan Paul
    FASEB JOURNAL, 2011, 25
  • [6] Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells
    Sohn, Bo Hwa
    Park, In Young
    Shin, Ji-Hyun
    Yim, Sun Young
    Lee, Ju-Seog
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2018, 50 : e421 - e421
  • [7] Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells
    Bo Hwa Sohn
    In Young Park
    Ji-Hyun Shin
    Sun Young Yim
    Ju-Seog Lee
    Experimental & Molecular Medicine, 2018, 50 : e421 - e421
  • [8] TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance
    Xia, Shunjie
    Ji, Lin
    Tao, Liye
    Pan, Yu
    Lin, Zhongjie
    Wan, Zhe
    Pan, Haoqi
    Zhao, Jie
    Cai, Liuxin
    Xu, Junjie
    Cai, Xiujun
    CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 2021, 12 (03): : 1121 - 1143
  • [9] TNF-alpha is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma
    Tan, Wenliang
    Luo, Xuan
    Li, Wenda
    Zhong, Jinyi
    Cao, Jun
    Zhu, Sicong
    Chen, Xianqing
    Zhou, Rui
    Shang, Changzhen
    Chen, Yajin
    EBIOMEDICINE, 2019, 40 : 446 - 456
  • [10] TAK1 is a novel therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance
    Xia, Shunjie
    Pan, Yu
    Xu, Junjie
    Cai, Xiujun
    JOURNAL OF HEPATOLOGY, 2020, 73 : S648 - S649